VivoSeq
Respiratory

Eosinophilic Esophagitis

60

Pipeline Programs↗

18

Active Trials↗

29

Companies Involved↗

Eosinophilic Esophagitis is a moderately active landscape with 60 programs across 29 companies. The most active players are Calypso Biotech BV, NImmune Biopharma, AbbVie. 9 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

11/100

Mech. Concentration

22/100

Completion Rate

81/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Calypso Biotech BV

1 program

Phase 1N

NImmune Biopharma

1 program

Phase 1AbbVie logo

AbbVie

1 program

Phase 1Novartis logo

Novartis

2 programs

Phase 2E

Ellodi Pharmaceuticals, LP

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical8

Montelukast

Organon and Co

DUPIXENT

Regeneron

Swallowed Fluticasone

Walter Reed Army Medical Center

Inhaled/swallowed Budesonide

University of North Carolina, Chapel Hill

Viscous/swallowed Budesonide

University of North Carolina, Chapel Hill

Phase 18

Montelukast Sodium

AstraZeneca

Beclomethasone Dipropionate

Schering-Plough

Sucralfate

AbbVie

Dexlansoprazole

Takeda

CALY-002

Calypso Biotech BV

Phase 229

Famotidine

Kenvue Brands

Vonoprazan

Phathom Pharmaceuticals, Inc.

Infliximab

Organon and Co

Losartan Potassium

Merck & Co.

Mepolizumab

Glaxo Dba Glaxosmithkline

Phase 36

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Benralizumab

AstraZeneca

Reslizumab

Teva

Tezepelumab

AstraZeneca

CC-93538

Bristol-Myers Squibb

Approved9

Omeprazole

Dexcel Pharma Technologies Ltd.

Fluticasone

Paratek Pharmaceuticals Inc

Lansoprazole

Takeda

Budesonide

Salix

Fluticasone Propionate

GSK

Analysis

Modality Breakdown

83%

Small molecule

48 of 58 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody1017%

Small molecule leads; the ring shows all 58 classified programs, each share of the total. Modality classified for 99% of 67 pipeline programs.

Analysis

Trial Status

91

clinical trials

Completed57 · 63%
Recruiting9 · 10%
Terminated8 · 9%
Active, not recruiting7 · 8%
Withdrawn5 · 5%
Unknown status2 · 2%
Other3 · 3%

Clinical Trials

Trial Activity

91 trials

A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
Recruiting·EEupraxia Pharmaceuticals Inc.·Phase 1/2·NCT05608681·117 enrolled
EDN and Eosinophilic Esophagitis
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT06387030·60 enrolled
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
Recruiting·Sanofi logoSanofi·N/A·NCT06695897·150 enrolled
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Recruiting·Regeneron logoRegeneron·N/A·NCT06693531·350 enrolled
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
Recruiting·UUniversity of California, San Diego·Phase 4·NCT06665971·30 enrolled
Zemaira Eosinophilic Esophagitis Pilot Study
Recruiting·—·Phase 2·NCT05485155·15 enrolled
Double-blind, Randomized, Non-inferiority Phase III Trial on the Efficacy and Tolerability of 2 mg Once Daily vs. 1 mg Twice Daily Budesonide Orodispersible Tablets in Adults With Eosinophilic Esophagitis
Recruiting·DDr. Falk Pharma GmbH·Phase 3·NCT06596252·308 enrolled
Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)
Recruiting·UUniversity of California, San Diego·N/A·NCT03980886·1,500 enrolled
PINNACLE: Etrasimod in Eosinophilic Esophagitis
Recruiting·Pfizer logoPfizer·Phase 2·NCT06800009·250 enrolled
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
Active, not recruiting·Sanofi logoSanofi·Phase 4·NCT06101095·69 enrolled
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Active, not recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT04991935·368 enrolled
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT05583227·368 enrolled
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
Active, not recruiting·UUniversity of Colorado, Denver·Phase 4·NCT04149470·90 enrolled
Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children
Active, not recruiting·—·N/A·NCT05309590·50 enrolled
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Active, not recruiting·UUniquity One (UNI)·Phase 2·NCT06598462·184 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)